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Summary The aim of this study was to examine pulmonary function after acute tymphoblastic leukaemia in childhood and identify risk factors
for reduced pulmonary function. We studied a population-based cohort of 94 survivors of acute lymphoblastic leukaemia in childhood who
were in first remission after treatment withut spinal irradiation or bone marrow transplantation. Pulmonary function test results were
compared with reference values for our laboratory, based on 348 healthy subjects who had never smoked from a local population study. A
median of 8 years after cessation of therapy (range 1-18 years) the participants had a slight, subclinical, restrictive ventilatory insufficiency
and reduced transfer factor and transfer coefficient. The changes in lung function were related to younger age at treatment and to more dose-
intensive treatment protocols that specified rnore use of cranial irradiation and higher cumulative doses of anthracyclines, cytosine
arabinoside and intravenous cyclophosphamide than previous protocols. We conclude that, 8 years after treatment without bone marrow
transplantation or spinal irradiation, survivors of childhood acute lymphoblastic leukaemia in first remission were without pulmonary
symptoms but had signs of slight restrictive pulmonary disease including reduced transferfactor. The increased dose intensity of many recent
protocols for childhood acute tymphoblastic leukaemia may lead to increased late pulmonary toxicity.
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Dunn the last decades the survival rate after childhood acute
lymphoblastic leukaemia (ALL) has been considerably improved
(Pui. 1995). Consequently. the frequency and severity of late
effects in survivors ofchildhood ALL have gained importance.
A few reports have been published on the lung function after
childhood leukaemia (Miller et al. 1986: Shaw et al. 1989: Jenney
et al. 1995: Turner-Gomes et al. 1996). Two groups of 15 and 31
childhood leukaemia survivors had a slight restrictive pulmonary
disease 3-7 years afterthe end oftherapy (Miller et al. 1986: Shaw
et al. 1989). In contrast. 19 ALL survivors in first remission had
normal lung volumes and transfer factor 4 years after the end of
therapy (Tumer-Gomes et al. 1996). None of these studies identi-
fied any risk factors for reduced pulmonary function.
In the largest study to date. 70 childhood leukaemia survivors.
examined 4 years after the end oftherapy. had lower lung volumes
and transfer factor than 146 matched control subjects (Jenney et al.
1995). Chest infections. cyclophosphamide and craniospinal irra-
diation were risk factors for reduced lung volumes. whereas chest
infections. doxorubicin. craniospinal irradiation and bone marrow
transplantation were risk factors for reduced transfer factor. Chest
infections were defined as the number of lower respiratory tract
infections requiring hospitalization during or subsequent to the
treatment for leukaemia. irrespective of whether or not an under-
lying cause was identified (Jenney et al, 1995).
Most ofthe previous studies had several limitations. such as few
participants. many patients lost to follow-up, short follow-up. lack
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of control groups. or many different diagnoses. stages of disease
and treatments included. The two largest studies (Shaw et al. 1989:
Jenney et al. 1995) both included patients treated with spinal irradi-
ation and patients treated with total body irradiation and bone
marrow transplantation. which are treatments known to cause
reduced pulmonary function (Jakacki et al. 1995: Nysom et al.
1996). Thus. the lung function of the majority of childhood ALL
survivors - patients in first remission treated without bone marrow
transplantation or spinal irradiation - is not well described.
We studied the pulmonary function of94 survivors ofchildhood
ALL who were in first remission several years after diagnosis and
had never been treated with bone marrow transplantation or spinal
irradiation.
PATIENTS AND METHODS
Patients
From the population-based Danish Cancer Registry (de Nully
Brown et al. 1989) 304 cases of ALL were identified. These
patients were at most 14 years old and diagnosed between 1970
and 1990 (inclusive) while residing in east Denmark. On 1 January
1993, 11 patients were still on therapy and 127 had died. Only four
patients who had emigrated were lost to follow-up.
Of 162 eligible patients. 128 (79%) gave their informed consent
to participate in the present study. Thirty-two patients declined to
participate for personal reasons, one was pregnant. and one had a
relapse before being studied. Two participants could not perform
the pulmonary function tests because of young age. To study the
pulmonary function after standard ALL therapy. we excluded 24
patients treated for a relapse. one treated for a second malignancy
and seven other patients treated with bone marrow transplantation.
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mediastinal irradiation or carmustine. This leaves 94 participants
offtherapy in first remission of ALL for the present analysis.
The median age of the participants was 3.9 years at diagnosis
(range 0.5-14.8 years). 6.9 years at completion of therapy
(3.5-19.7 years) and 16.2 years at time of the study (5.3-34.2
years). The median length offollow-up was 10.6 years from diag-
nosis (3.4-23.4 years) and 7.6 years from completion of therapy
(1.2-18.3 years).
The participants had received chemotherapy and cranial irradia-
tion as described in Table 1. The dose of cranial irradiation was
15-18 Gy (n = 23) or 24 Gy (n = 16). No participants received
other types ofirradiation.
The height of the participants at time of the study ranged from
119 to 179 cm in female subjects and from 110 to 185 cm in male
subjects. The average height did not differ significantly from
national reference data (mean standardized residual -0.1. 95%
confidence interval -0.3 to 0.1. range -2.1 to 3.0) (Andersen et al.
1982). Participants who had received cranial irradiation were
significantly shorter than the other participants (estimated differ-
ence between means 0.8 standardized residual. 95% confidence
interval 0.4-1.2). but their sitting height to standing height ratio
did not differ significantly from local reference data (Holm. 1996).
At the time ofthe study 18 participants smoked, four had previ-
ously smoked. whereas 72 had never smoked. The four who had
previously smoked were all considered as smoking subjects as
they had consumed the same median amount of cigarettes as the
18 current smoking subjects and as they had stopped smoking only
2-17 months before being studied. This gave a group of 22
smoking subjects in all (seven men. P = 0.05 for more women who
smoked). who had consumed a median of 1.5 pack-years of
cigarettes (1 pack-year is 20 cigarettes a day for 1 year: range
0.1-10.5) over a median period of 3 years ( 1-13 years).
Pulmonary function testing
All pulmonary function tests were performed in the same labora-
tory in accordance with the European recommendations (Quanjer
and Tammeling. 1983). The forced expiratory volume in 1 second
(FEVd) and the forced vital capacity (FVC) were measured with a
pneumotachograph (Jaeger. Germany). In patients who terminated
the forced expiration in less than 1 s. the forced expiratory volume
in 0.5 s was recorded instead. The ratio of FEV /FVC was calcu-
lated as a percentage. Flow-volume curves were evaluated by one
ofus (BH). Total lung capacity (TLC) was measuredby the helium
dilution technique (Jaeger. Germany) and the transfer factor for
carbon monoxide with the single-breath technique according to
the recommendations given by the American Thoracic Society
(Anonymous. 1987). except that TLC and transfer factor were
only determined once if cooperation was good. The equipment
detected carbon monoxide with an infrared spectrophotometer
(Jaeger, Germany) and helium with a thermal conductivity
method. The transfer coefficient was calculated as transfer factor
divided by alveolar volume.
Pulmonary function test results were compared with reference
values for our laboratory. which were generated by adjusting,
published reference values (Quanjer and Tanmmeling. 1983:
Table 1 Treatment protocols
Protocol n Induction Consolidtion CNS VCR/ Anthra- Cyclo- Unusal
prophyaxis PREDa cyclines phosphamide ces
70-76 14 VCRIPRED - + - CYCorally(0.8-4.3grrM2n=6)
-*L-ASP (from 1974) CYC (0.9 gm-2)/Ara-C, no 6MP
(n = 1)
77-81 19 VCR/PRED -L-ASP - IDM x3< + -e - No IDM (n = 2)
81 SR 8 VCR/PRED -*L-ASP - IDM x3 - - -
81 IR 11 VCRIPRED/DOX-*L-ASP - HDMx8 + 120DOX - <1983(n=2); noHDM but
IDM and more reinductons
81 HR 10 VCR/PRED/DOXJL-ASP CYC/Ara-C/6TG+VCR RT + 200 DOX 4000
/PRED/DOX/L-ASP
86 SR 6 VCR/PRED/DOX -iL-ASP - HDM x8 + 120 DOX -
86 IR 17 VCR/PRED/DNR -iL-ASP CYC/Ara-C/6TG +VCR IDM x4 - 120 DOX 3000
/DEXADOX/L-ASP + RT 120 DNR
86 HR 7 PRED-*DEX/CYC/Ara- DOX. CYC, Ara-C. IDM x6 - 120 DOX 5000
CNM-26/1DM VM-26, 6TG + RT 120 DNR
VCR/DEXfDNR/L-ASP
Other 1 VCR/PRED/DOX -*L-ASP CYC - + 75 DOX 600 No protocol
1 - CYC/Ara-CflFOS HDM - 191 DOX 6700 Riehm 83 B-ALL protocol
+ VP-16NM-26 + triple'
All parbcipants received intrathecal methotrexate and maintenance terapy with oral 6-mercaptopurine and methotrexate. Parbcipants diagnosed after May
1981 were treated according to protocols of the Nordic Society of Paediatric Haematology and Oncology (NOPHO) (Schroder et al, 1995). Doses of
anthracyclines and cyclophosphamide are given as cumulative mg m-2 of body surface area; 6MP, 6 -mercaptopurine; 6TG, 6-thioguanine; Ara-C, cytosine
arabinoside; CNS, central nervous system; CYC, intravenous cyclophosphanide; DEX, dexamethasone; DNR, daunorubicin; DOX, doxorubidn; HDM high-
dose methotrexate (1 g m-2); HR, high risk; IDM, intermediate-dose methotrexate (0.5 g m -2); IFOS, ifosfamide; IR, intermediate risk; L-ASP, /-asparaginase;
MTX, methotrexate: PRED, prednusone; RT, radiotherapy of the CNS; SR, standard risk; VCR, vincristine; VM-26, teneposide; VP-16, etoposide. aVCR and
PRED reinductions; Othree patients also received RT; cone patient received 23 mg m-2, one 120 mg m-2 and one 281 mg m-2 of DNR; ftwo patients also received
RT; etwo patients received 75 mg mr-2 of DNR for suspected, but never confirmed, relapse; tMTX 4 g m-2 and MTXImethylPRED/Ara-C intrathecally.
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Rosenthal et al. 1993; Quanjer et al. 1995: Stam et al. 1996) to fit
348 healthy 13- to 24-year-old Caucasian subjects who had never
smoked from a local population study (Nysom et al. 1997). The
height of the control subjects ranged from 143 to 182 cm in
women and from 147 to 200 cm in men. In addition to evaluating
each individual pulmonary function test variable, an integrated
evaluation of the pulmonary function was also performed, based
on the combination of the different variables. The evaluation was
carried out without knowledge ofthe leukaemia treatmentprotocol
of the patient. Pulmonary function was classified as (a) restrictive
pattem (reduced FVC or TLC: with or without reduced transfer
factor or coefficient; normal or elevated FEV1/FVC): (b) restric-
tive flow-volume curve pattem but with volumes and capacities
within reference limits: (c) reduced transfer factor ortransfer coef-
ficient with normal lung volumes and flow-volume curves; (d)
obstructive pattem (low FEV1/FVC); or (e) normal.
Data analysis
To make data comparable, pulmonary function test results and
heights were analysed as standardized residuals: (observed value -
predicted value) divided by the residual standard deviation
(Quanjer and Tammeling, 1983). Standardized residuals are
equivalent to standard deviation (Z) scores. The distribution of
pulmonary function test results and heights did not differ signifi-
cantly from a normal distribution (Shapiro-Wlk test), so these
results are given as mean values, 95% confidence intervals of
mean and ranges. All otherdata are reported as median values with
ranges. Student's t-test was used for determining whether height
and pulmonary function test results differed significantly from the
reference values (i.e. a standardized residual of 0), and for
comparing the results of groups of patients. Pulmonary function
test results were considered abnormal if they were more than
1.645 residual standard deviation from the predicted mean value
(Quanjer and Tammeling. 1983). If raised as well as reduced
values of a variable are considered abnormal (TLC, FEV1/FVC,
transfer coefficient) this corresponds to two-sided 90%c prediction
limits for reference data. If only reduced values are considered
abnormal (FVC. FEVI. transfer factor) this corresponds to one-
sided 95%7 limits. Parametric (Pearson) and non-parametric
(Spearman) correlation analysis and simple and multiple linear
regression models were used according to the distribution of data
to evaluate possible predictive variables ofpulmonary function. In
the multiple regression analysis. variables that did not significantly
improve the models were removed. one at a time. in a step-down
procedure. The continuity adjusted chi-square test and
Mann-Whitney's unpaired test were used for comparing baseline
characteristics between groups of patients (Altman, 1991).
Probabilities below 0.05 were considered statistically significant
and data were analysed using the SAS computer software package
(SAS Institute. Cary. NC. USA).
Ethics
All participants and the parents of the children younger than 18
gave their written informed consent. The study was in accordance
with the Helsinki II declaration and was approved by the local
medical ethics committee ofCopenhagen. Denmark (approval no.
KF V92-097).
RESULTS
Participants
At the time of the study one participant received captopnrl for
arterial hypertension. and one used beclomethasone inhalations
for asthma Ten participants had pulmonary symptoms: one
complained of dyspnoea. two complained of cough at night. five
complained ofcough on exertion. one complained ofcough at night
and on exertion, whereas one complained ofdyspnoea and cough at
night Eighty-four participants had no pulmonarv symptoms.
Fourteen participants (including five smoking subjects) considered
their physical work capacity better than that ofother people oftheir
own age, 63 (14 smoking subjects) considered it equal to that of
other people of their own age. 14 (three smoking subjects) consid-
ered it abit inferior, and three (non-smoking subjects) much inferior.
Five participants had haemoglobin concentrations 0.2-1.1 dl-'
below the lower limits of normal of our laboratory. All others had
values evenly distributed within the normal range of our laboratory
(5-7 years: 11.9-14.8, 7-13 years: 12.1-15.6. female subjects > 13
years: 11.3-16.1. male subjects >13 years: 12.9-17.7 gdl- ).
Table 2 Pulmonary functn test results
Variable Number evaluable Mean (95% Cl) Range Numberwith reduced/
raised valuesa
Forced vital capacity 94 -0.4 (-0.6 to -0.2) -2.9-2.3 14/3
Forced expiratory volume in 1 s 83 -0.2 (-0.5 to -0.01) -2.6-3.1 7/4
Ratio of FEV1 to FVC 83 0.1 (-0.1 to 0.3) -2.4-2.0 1/5
Total lung capacity 89 -0.2 (-0.5 to -0.03) -2.1-2.3 10/5
Transfer factor
Non-smokers 67 -0.4 (-0.7 to -0.2) -3.4-1.7 9/1
Smokers 22 -0.7 (-1.0 to -0.4) -2.0-0.8 3/0
Transfer coefficient
Non-smokers 66 -0.3 (-0.5 to -0. ) -2.2-2.0 4/2
Smokers 22 -0.9 (-1.4 to -0.4) -2.9-1.5 6/0
Results are given as standardized residuals; Cl confidence interval; FEVJ, forced expiratory volume in 1 s; FVC, forced vital capacity; astandardized residuals
<-1.645 / >1.645.
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Lung volumes
Pulmonary function test results (Table 2) were poorly related to
self-estimated physical work capacity (plots not shown). and only
four of the ten participants with pulmonary symptoms had
abnormal pulmonary function tests. Similarly. standardized
residuals for lung function and height were not related (plots not
shown). For five participants measurements of TLC and transfer
factor were impossible because ofpoor co-operation at the single-
breath procedure.
The mean FVC. FEVI and TLC standardized residuals were all
slightly, but significantly reduced. and 7-14 participants (one
smoking subject) had values below the fifth percentile (Table 2).
In 11 participants. the forced expiration was terminated in less
than 1 s, but in ten of these the forced expiratory volume in 0.5 s
was larger than the predictedFEVI.
FEVIFVC ratio and flow-volume curves
Tlhe mean FEV,/FVC standardized residual was normal (Table 2).
Two flow-volume curves were classified as obstructive, and one
was also restrictive. None of these curves were from smoking
subjects or patients with short expirations. Eighteen other
flow-volume curves appeared restrictive, including the curves of
seven patients (one smoking subject) with a low TLC.
Transfer factor and transfer coefficient
The mean transfer factor and transfer coefficient standardized
residuals were significantly reduced both in non-smoking subjects
and in smoking subjects (Table 2).
The transfer factor values given were not corrected for haemo-
globin concentration in the present study because the reference
values for pulmonary function for our laboratory were based on
transfer factor measurements without haemoglobim correction and
because the haemoglobin concentration of nearly all participants
was within normal limits. Correcting the transfer factor to the
average age-specific haemoglobin concentration of our laboratory
according to the equation of Cotes (Quanjer and Tammeling.
1983) had no influence on conclusions concerning transfer factor
(data not shown).
Integrated evaluation of pulmonary function
When all available measures of pulmonary function were consid-
ered together, 25 participants (one smoking subject) had a restric-
tive pattern, six ofthem with normal lung volumes and capacities.
Ten (six smoking subjects) had a reduced transfer factor ortransfer
coefficient with normal lung volumes and flow-volume curves,
and two (one smoking subject) had an obstructive pattern. Sixty-
one per cent of the participants were estimated to have a normal
pulmonary function.
Risk factors for reduced pulmonary function
The age at diagnosis and the length of follow-up after diagnosis
were not significantly different for patients with a reduced TLC and
patients without a reduced TLC, but nine out of ten patients with a
reduced ThC hadbeen treated according to the intermediate orhigh-
risk protocols of the 1980s (Table 1). These protocols used more
cytosine arabinoside. 6-thioguanine. anthracyclines and intravenous
Table 3 Regression models for total lung capacity
Variable P Regression co (95% Cl) P
Simple regression models
Doxorubicin (mg r-2) 0.03 -0.0022 (-0.0051 to 0.0007) 0.13
Daunorubicin (mg m-2) 0.01 -0.0018 (-0.0055 to 0.0019) 0.3
Cycophophamide intravenously (g m-2) 0.04 -0.11 (-0.23 to 0.01) 0.07
Cytosine arabinoside (g r-2) 0.05 -0.26 (-0.50 to -0.02) 0.04
6-Thioguanine (g m2) 0.03 -0.39 (-0.89 to 0.11) 0.12
Anthracycines (mg M-2)t 0.03 -0.0017 (-0.0038 to 0.0003) 0.10
High-dose methotrexate (number of cycles) 0.00 -0.0056 (-0.0852 to 0.0740) 0.9
Cranial irradiation 0.05 -0.45 (-0.88 to -0.02) 0.04
Intermediate- or high-risk protococ 0.03 -0.36 (-0.79 to 0.06) 0.09
Srnoking 0.02 +0.31 (-0.18 to 0.80) 0.2
Female sex 0.00 +0.024 (-0.40 to 0.45) 0.9
Follow-up after diagnosis (years) 0.04 +0.036 (-0.004 to 0.076) 0.08
Age at diagnosis (years) 0.05 +0.055 (0.001 to 0.109) 0.045
Age at follow-up (years) 0.08 +0.044 (0.012 to 0.076) 0.01
Multple regression models0
Doxorubicin 0.09 -0.0063 (-0.0107 to -0.0020) 0.005
Doxorubicin x age at diagnosise +0.00065 (0.00013 to 0.00116) 0.01
Cycophosphamide intravenously 0.10 -0.14 (-0.25 to -0.02) 0.02
Age at diagnosis +0.068 (0.014 to 0.122) 0.01
Cytosine arabinoside 0.11 -0.30 (-0.54 to-0.07) 0.01
Age at diagnosis +0.066 (0.012 to 0.119) 0.02
Cranial irradiation 0.11 -0.53 (-0.95 to -0.11) 0.01
Age at diagnosis +0.066 (0.013 to 0.119) 0.02
Intermediate- or high-risk protocol 0.09 -0.89 (-1.50 to -0.28) 0.005
Intermediate- or high-risk protocol x age at diagnosise +0.085 (0.012 to 0.157) 0.02
Cl, confidence interval; 411 of a model indicates how large a proportion of the total variaton the model explains; bcumulative dose of doxorubicin + daunorubicin;
cthe intermediate and high-riskprotocolsfrom 81 and 86 (Table 1); 0daunorubicin, anthracyclines, and 6-thioguanine werenon-significant in the mutiple
regression models, and consequentty were removed during the backward selction procedure; Interaction term (see text).
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cyclophosphamide than the other protocols. The mean TLC was
-0.4 (-0.8 to-0.1) in40patients tratedaccording tointermediate or
high-risk protcols, compared with -0.1 (-0.3-02) in the 49 other
patients (estimated difference between means 0.4 standardized
residual, 95% confidence interval-0.1-0.8).
Using simple and multiple linear regression analysis we
analysed the relationship between TLC standardized residual and
cumulative doses ofthe five most characteristic drugs ofthe inter-
mediate and high-risk protocols (doxorubicin, daunorubicin, intra-
venous cyclophosphamide, cytosine arabinoside, 6-thioguanine),
the dose ofanthracyclines (doxorubicin plus daunorubicin doses),
the number of high-dose methotrexate cycles, cranial irradiation,
treatment according to intermediate or high-risk protocols,
smoking, sex, the length offollow-up afterdiagnosis and the ages
at diagnosis and follow-up (Table 3). In the simple regression
analysis there was a significant relationship between a lower TLC
and a larger cumulative dose ofcytosine arabinoside, cranial irra-
diation, younger age atdiagnosis and younger age atfollow-up.
The cumulative doses of the five drugs considered and the use
of cranial irradiation were all strongly correlated with each other
(P < 0.00001 except for doxorubicin with daunoubicin when
P =0.008). Therefore, testing several of these variables in one
multiple regression model would be meaningless. As age at diag-
nosis was not significantly correlated with any of these variables,
we subsequently tested multiple regression models considering
age at diagnosis, one ofthe five drugs mentioned or cranial irradi-
ation and a term representing interaction between the treatment
variable and age at diagnosis. Astatistically significant interaction
term indicates that the pulmonary toxicity of a certain treatment
depends on the age at which this treatment is given. Variables that
did not improve the models significantly were removed, one at a
time, and the resulting models are shown in Table 3. Age at follow-
up was significantly correlated with TLC and also with the treat-
ment related variables considered (non-parametric correlation
coefficient -0.37 to -0.59, P <0.0002). Neither age at follow-up,
length of follow-up, nor smoking improved any of the multiple
regression models significantly.
When we applied the multiple regression models in Table 3 to
the 52 participants who were within theheight and age range ofthe
local control group, the estimated regression coefficients were all
within the confidence intervals given in Table 3. However, the esti-
mated confidence intervals were wider than the confidence inter-
vals based on all 89 participants and most regression coefficients
were not statistically significant.
The significant independent variables ofthe multiple regression
models for TLC were subsequently tested for their ability to
predict FVC and FEV1. Although 6 out of 20 regression coeffi-
cients for FVC or FEV, were not statistically significant
(P =0.05-0.13) their estimated signs and values were in accor-
dance with themultiple regression models forTLC. Nine ofthe 14
patients with a reduced FVC, and four ofthe seven patients with a
reduced FEV1 had been teated according to the intrmeiate or
high-risk protocols.
Patients trated according to the intermediate orhigh-risk proto-
cols accounted for 7 (no smoking subject) ofthe 12 patients with
an abnormally low transfer factor, and for five (two smoking
subjects) ofthe ten patients with a low transfercoefficient. Four of
the patients with a low transfer factor also had a low TLC. The
transfer factor and TLC were strongly correlated (parametnc
correlation coefficient 0.56, P < 0.0001), and a model for the
transfer factor was ftuther improved by adding the smoking state
[regression coefficients +0.57 (95% confidence interval 0.40-0.75,
TLC) and -0.46 (-0.85 to -0.06, smoker)]. None of the other
thireen variables considered for predicting the TLC (Table 3)
significantly improved this model when they were entered one at a
time (P = 0.08-0.84).
At the integrated evaluation of pulmonary function, the
frequency of pulmonary abnormalities was significantly higher
among patients treated according to the intmediate or high-risk
protocols (23 of45) than among the remaining patients (14 of49,
P =0.04).
DISCUSSION
Eight years after cessation of treatment for ALL, several of our
participants had a subclinical, restrictive ventilatory insufficiency
based on TLC and a high frequency of restrictive flow-volume
curve pattems. The changes in lung function were related to
youngerage at treatmentandtothedose-intensive treatnentproto-
cols ofthe 1980s that specified highercumulative doses ofanthra-
cyclines, intravenous cyclophosphamide and cytosine arabinoside,
and more frequent use ofcranial irradiation, than previous proto-
cols.Thechanges were slight: according to theEuropean reference
values (Quanjer and Tammeling, 1983) the average TLC of -0.4
standardized residual in the intermediate or high-risk patients
means aTLC of7.02 1 for a 180-cm-tall male adultcompared with
apredicted valueof7.30 1, whichcorresponds to a loss ofonly4%.
The participants were treated according to several different
protocols that, however, represent twobasic concepts ofchildhood
ALL therapy: the more simple protocols based on vincrisine,
prednisone, I-asparagnase, methotrexate and 6-mercaptopunne,
and the more intensive regimens when cranial irradiation, anthra-
cyclines, alkylating agents, epipodophyllotoxins and antimetabo-
lites otherthan methotrexate or6-mercaptopurine were added.
The five statistically significant multiple regression models for
TLC included age at diagnosis and treatment-related risk factors.
The latter comprised treatment according to intermediate or high-
risk protocols or treatments characteristic of these protocols
(doxorubicin, intravenous cyclophosphamide, cytosine arabi-
noside, cranial irradiation). The treatment-related riskfactors were
closely interrelated and thus could not be tested against each other.
All the models related a lower TLC to cranial irradiation, higher
cumulative drug doses and younger age at diagnosis. Our study
demonstrates for the first time that therapy for ALL is more lung
toxic in young children, a hypodtsis previously put forward
(Shaw et al, 1989).
The cumulative dose of doxorubicin was a risk factor for
reduced TLC in the multiple regression analysis. However, neither
the cumulative dose of daunorubicin nor the sum of the doxo-
rubicin and danoubicin doses were statistically sinificant. This
suggests that doxorubicin may be lung toxic, rather than anthra-
cyclines as a group.
Doxorubicin was a risk factor for reduced transfer factor,
cyclophosphamide was a risk factor for reduced lung volumes and
cranial irrdiation was a risk factor for reduced FEV, in a previous
study of leukaemia survivors (Jenney et al, 1995). The auths did
not report whether the potential explanatory variables were corre-
lated as in the present study, but, if so, it is likely that different
tratmentvariablespredicteddifferentpulmonary functiontestpara-
meter. In that case, our results on lung volumes and transfer factor
are in full accordance with thoseofJenney et al (1995). Chestinfec-
tions, craniospinal irradiation, and bone marrow ransplantation
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were also risk factors for reduced lung function in the study by
Jenney et al (1995). As we excluded patients trated with cranio-
spinal irradiation or bone marrow transplantation and as we did not
test chest infections as an explanatoy variable, we could not eval-
uate the influence ofthese factors.
Cranial inradiation was apparently a risk factor for reduced TLC
in our multiple regression analysis. This may be because persons
teated with cranial irradiation had abnormal body proportions,
which resulted in an inadequately high predicted lung fimction.
However, the body proportions of the participants were normal,
and reduced lung function was not related to height It therefore
seems more likely that cranial irradiation was significant in our
regression models simply because it reflects the more dose-
intensive reatment protocols.
Age at follow-up was the strongest predictor of TLC in the
simple regression models (Table 3). This could be explained by a
gradual recovery ofpulmonary function over decades after the end
ofchemotherapy. However, there was also a significant correlation
between age at follow-up and the doses ofthe drugs in the multiple
regression models. It therefore seems more likely that age at
follow-up was significant in a simple regression model because it
reflects the change in treatment protocols.
Most participants with reduced transfer coefficient smoked.
This, and the fact that the best regression model of transfer factor
included only TLC and tobacco smoking, indicates that the
reduced transfer factor after chemothrapy seems to be caused
mainly by reduced lung volumes. The present data therefore do not
suggest thickening of the pulmonary diffusion membrane or
reduced pulmonary capillary blood volume.
Methotrexate treatment was related to lung toxicity in some
early studies (Clarysse et al, 1969; Nesbit et al, 1976). In contrast,
the more recent studies found no lung toxicity of methotrexate
(Miller et al, 1986; Shaw et al, 1989; Jenney et al, 1995). The
present data support the latter finding because lung function was
not associated with the number of high-dose methotrexate cycles
and because the TLC was normal in the 49 patients teated
according to other than intermediate or high-risk protocols,
although these patients received a higher cumulative dose oforal
methotrexate than patients treated according to intermediate or
high-risk protocols (data not shown). Cytosine arabinoside has
been reported to cause acute pulmonary oedema (Shearer et al,
1994), but usually after higher doses than those received by our
patients. Cytosine arabinoside has not previously been linked to
abnormal pulmonary function tests.
Anthracyclines could affect the lung function by inducing
congestive heart failure. The cumulative doses of andtracyclines
receivedby ourparticipants, however, were lowerthan what has yet
been reported to cause late clinical cardiotoxicity (Lipshultz et aL
1991; Steinherz et al, 1991), and only a few patients reported any
cardiopulmonary symptoms, which makes this explanation unlikely.
In alargepopulation study the transferfactor was reduced shortly
after the onset ofsmoking, whereas lung volumes were unchanged
during the first decade ofsmoking (Knudson et al, 1989). Our data
were in accordance with this and did not suggest increased
pulmonary toxicity of tobacco smoing in survivors of childhood
ALL compared with the background population. However, because
ofthe small sample size and the relatively mild tobacco exposure of
participants, our study does not have the stanstical powerto exclude
a clinically relevant increased toxicity of tobacco smoking in those
reated with chemothrapy in childood. Tobacco smoking is
undoubtedly toxic to the lung, childhood cancer survivors are at
increased risk ofdeveloping second malignant neoplasms, and many
of them have had subclinical damage to several organs causing a
reduced functional reserve. Consequently, long-term survivors of
childhood cancer should be eagerly warned against tobacco
smoking, irrespective of whether the tobacco toxicity to their lungs
is actually greater than in the background population or not.
As in a previous study (Jenney et al, 1995), pulnonary function
correlated poorly with self-estimated physical work capacity.
Thus, self-esimated physical work capacity can apparently not be
used for screening patients for reduced pulnonary function. The
prevalence of asthmatic symptoms was lower in our participants
than reported in a local population survey study (Backer, 1995).
Selection bias should not influence our results because patients
and controls were selected from population-based cohorts and a
high percentage of eligible subjects participated. It is a limitation
ofour study that the age and heightrange ofparticipants was wider
than that of control subjects. However, our local predictive equa-
tions for lung function were generated by adjusting the best avail-
able predictive equations from the litrature to fit the large group
of local control subjects optimally. The reference equations from
the literature that we adjusted are based on subjects covering the
full height and age range ofourparticipants. Furthermore, the esti-
mated regression coefficients of our multiple regression models
were only minimally affected by limiting the analysis to patients
within the height and age range ofthe control subjects.
The present study was cross-sectional in design and treatment
was non-randomly assigned. Consequently, year of diagnosis,
lengthoffollow-up, age atfollow-up, riskgroup and type oftherapy
were all closely related and could therefore not be tested against
eachother. A cohorteffectmustbe considered as asource oferrorin
across-sectional study, but theexpected cohort effect would tend to
cause the opposite results ofwhat was found. Ifthe drugs given had
similarpulonary toxicity, patientsteated duringthe last partofthe
study period would beexpected to have suffered less complications
during therapy than patients teated during the first part because of
improved supportive care and increasing clinical experience. In
contrast with this, patients teated during the last part of the study
period acully experienced morepuhlonary toxicity.
Studies oflate effects are historic in nature: when the long-term
toxicity ofa treatment protocol is assessable the protocol itselfhas
often been revised several times already, thus necessitating a study
of the late effects of the altered prtocol. The recent tendency to
increase the dose intensity of treatment protocols for a number of
childhood cancers also calls fornew studies oflate effects. Using a
repeated follow-up study of the present cohort, it would be
possible to determine whether pulmonary function recovers, stays
unchanged or deteriorates late after childhood ALL.
In conclusion, several years after therapy for childhood ALL,
participants had a subclinical, slight restrictive pulmonary disease
including reduced transfer factor. The reducedpulnonary function
was related to young age at tratment and to more dose-intensive
protocols. The abnormalities appear mild, but the limited number
of patients studied to date, the cross-sectional design of the few
available studies and the increased dose intensity of many recent
ALL protocols make long-term clinical follow-up of survivors of
childhood ALL necessary.
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